RayKnowChina Research Map
Shortlist

Beijing

Sanbo Brain Hospital

首都医科大学三博脑科医院

Listed for 2 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Sanbo Brain Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Glioma胶质瘤30 papers led1 open trial led
  2. Chordoma脊索瘤2 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Lung cancer, Pancreatic cancer, Breast cancer, Hepatoblastoma, Retinoblastoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Glioma

胶质瘤

Led 30 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.4%.

Papers led
30
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 7720212022: 1120222023: 5520232024: 111120242025: 662025

14 hospitals in Beijing for glioma187 hospitals in China for glioma

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT07126990

    Age 18 years to 80 years (registered criteria)

    Led by Sanbo Brain HospitalBeijing

  2. Recruiting
    A Phase I Clinical Study of YN003 in the Treatment of Glioma
    Phase
    Phase 1
    Started
    2026-10
    Posted
    Registry
    NCT07929909

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  3. Recruiting
    SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05303519

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Shanghai

  4. Recruiting
    Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
    Phase
    Phase 1
    Started
    2023-01
    Posted
    Registry
    NCT05717699

    Age 1 year to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  5. Recruiting
    Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
    Phase
    Phase 1
    Started
    2023-01
    Posted
    Registry
    NCT05717712

    Age 1 year to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  6. Not yet recruiting
    A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07472790

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  7. Enrolling by invitation
    Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06763965

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurosurgeryMedical oncologyPathology / laboratory medicineRadiology / nuclear medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led30
  1. NIBAN2 Stimulates Glioma Growth by Regulating the JAK2/STAT3/c-Myc Pathway.2025Cancer medicineFree full text
  2. Comprehensive analysis of heat shock proteins in glioma revealed the association with glioma-associated myeloid cells.2025Genes and immunityFree full text
  3. Leptomeningeal dissemination in H3 K27M- mutant diffuse midline gliomas: clinical characteristics, risk factors, and prognostic insights.2025Journal of neuro-oncologyFree full text
  4. The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials.2025Nature communicationsFree full text
  5. Clinical characteristics and detection of MYB-QKI fusions in patients with angiocentric glioma.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
  6. SKP2 protein as a prognostic biomarker for glioma and promotes tumor progression by regulating the cell cycle.2025Scientific reportsFree full text
  7. Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy.2024BMC cancerFree full text
  8. Ganglioglioma with MAP2K1 Mutation and CDKN2A/B Homozygous Deletion: A Case Report.2024British journal of hospital medicine (London, England : 2005)
  9. Postoperative hydrocephalus is a high-risk lethal factor for patients with low-grade optic pathway glioma.2024British journal of neurosurgery
  10. High expression of SIGLEC7 may promote M2-type macrophage polarization leading to adverse prognosis in glioma patients.2024Frontiers in immunologyFree full text
  11. Retinol dehydrogenase 10 promotes epithelial-mesenchymal transition in spinal cord gliomas via PI3K/AKT pathway.2024International journal of immunopathology and pharmacologyFree full text
  12. Epithelial-Mesenchymal Transition Related Score Functions as a Predictive Tool for Immunotherapy and Candidate Drugs in Glioma.2024Journal of chemical information and modeling
  13. Impact of Microsurgery and Postoperative Radiotherapy on Neurological Function in Intramedullary Spinal Cord Gliomas.2024Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  14. Oncolytic virus Ad-TD-nsIL-12 inhibits glioma growth and reprograms the tumor immune microenvironment.2024Life sciences
  15. Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trial.2024Nature communicationsFree full text
  16. Advances in Molecular Pathology, Diagnosis and Treatment of Spinal Cord Astrocytomas.2024Technology in cancer research & treatmentFree full text
  17. Practical Nomograms and Risk Stratification System for Predicting the Overall and Cancer-specific Survival in Patients with Anaplastic Astrocytoma.2024World neurosurgery
  18. Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  19. Epithelial-mesenchymal transition is the main way in which glioma-associated microglia/macrophages promote glioma progression.2023Frontiers in immunologyFree full text
  20. Cuproptosis-related gene SLC31A1 expression correlates with the prognosis and tumor immune microenvironment in glioma.2023Functional & integrative genomicsFree full text
  21. Leptomeningeal spread in high-grade gliomas: Is surgery or adjuvant therapy after leptomeningeal spread associated with survival benefit?2023Neurosurgical reviewFree full text
  22. Mutation-derived, genomic instability-associated lncRNAs are prognostic markers in gliomas.2023PeerJFree full text
  23. Proteomic Distributions in CD34+ Microvascular Niche Patterns of Glioblastoma.2022The journal of histochemistry and cytochemistry : official journal of the Histochemistry SocietyFree full text
  24. Sensitive Detection and Conjoint Analysis of Promoter Methylation by Conjugated Polymers for Differential Diagnosis and Prognosis of Glioma.2021ACS applied materials & interfaces
  25. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.2021AgingFree full text
  26. The concept of "Four Walls, Two Poles" in the lesions of the thalamus and ganglion regions: case report and literature review.2021BMC surgeryFree full text
  27. Molecular Characterization of AEBP1 at Transcriptional Level in Glioma.2021BioMed research internationalFree full text
  28. Development of a prognostic model based on an immunogenomic landscape analysis of medulloblastoma.2021Bioscience reportsFree full text
  29. LINC00887 aggravates the malignant progression of glioma via upregulating CCND1.2021European review for medical and pharmacological sciences
  30. The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study.2021Journal of cancer research and clinical oncologyFree full text
Chinese-language papers (not in the count)1
  1. [Clinicopathological characteristics of H3K27-altered diffuse midline glioma and evaluation of NTRK as its therapeutic target].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status9
  1. Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade GliomaEnrolling by invitationNCT07126990Lead (inferred)Phase 1/Phase 2Start 2025-02
  2. A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade GliomaNot yet recruitingNCT07472790Study sitePhase 1Start 2026-07
  3. A Phase I Clinical Study of YN003 in the Treatment of GliomaRecruitingNCT07929909Study sitePhase 1Start 2026-10
  4. Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.Enrolling by invitationNCT06763965Study sitePhase 1/Phase 2Start 2024-11
  5. Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine GliomaRecruitingNCT05717699Study sitePhase 1Start 2023-01
  6. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)RecruitingNCT05303519Study sitePhase 3Start 2023-06
  7. Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine GliomaRecruitingNCT05717712Study sitePhase 1Start 2023-01
  8. Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 MutationActive, not recruitingNCT06780930Study sitePhase 3Start 2024-10
  9. A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1CompletedNCT03776071Study sitePhase 3Start 2020-12

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 2 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

9 hospitals in Beijing for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryPathology / laboratory medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

首都医科大学三博脑科医院

Sanbo Brain Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Beijing Sanbo Brain Hospital; 北京三博脑科医院

Suggest a correctionDownload the data